In the past week, LENZ stock has gone up by 4.47%, with a monthly decline of -6.69% and a quarterly plunge of -28.56%. The volatility ratio for the week is 7.48%, and the volatility levels for the last 30 days are 6.05% for LENZ Therapeutics Inc The simple moving average for the last 20 days is 1.74% for LENZ stock, with a simple moving average of -4.99% for the last 200 days.
Is It Worth Investing in LENZ Therapeutics Inc (NASDAQ: LENZ) Right Now?
The 36-month beta value for LENZ is at 0.54. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LENZ is 22.58M, and currently, shorts hold a 11.29% of that float. The average trading volume for LENZ on March 18, 2025 was 164.44K shares.
LENZ) stock’s latest price update
LENZ Therapeutics Inc (NASDAQ: LENZ)’s stock price has decreased by -7.31 compared to its previous closing price of 25.45. However, the company has seen a 4.47% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-11 that SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, March 19, 2025, at 4:30 p.m. EST to report its fourth quarter and full year 2024 financial results and recent corporate highlights.
Analysts’ Opinion of LENZ
Many brokerage firms have already submitted their reports for LENZ stocks, with Raymond James repeating the rating for LENZ by listing it as a “Outperform.” The predicted price for LENZ in the upcoming period, according to Raymond James is $37 based on the research report published on September 27, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LENZ reach a price target of $38. The rating they have provided for LENZ stocks is “Buy” according to the report published on August 12th, 2024.
LENZ Trading at -3.15% from the 50-Day Moving Average
After a stumble in the market that brought LENZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.40% of loss for the given period.
Volatility was left at 6.05%, however, over the last 30 days, the volatility rate increased by 7.48%, as shares sank -6.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.29% lower at present.
During the last 5 trading sessions, LENZ rose by +4.47%, which changed the moving average for the period of 200-days by +53.28% in comparison to the 20-day moving average, which settled at $23.19. In addition, LENZ Therapeutics Inc saw -18.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LENZ starting from Chevallard Daniel R., who purchase 3,188 shares at the price of $15.68 back on May 14 ’24. After this action, Chevallard Daniel R. now owns 3,188 shares of LENZ Therapeutics Inc, valued at $49,988 using the latest closing price.
MCCOLLUM JAMES W, the Director of LENZ Therapeutics Inc, purchase 31,332 shares at $15.99 during a trade that took place back on May 13 ’24, which means that MCCOLLUM JAMES W is holding 525,565 shares at $501,093 based on the most recent closing price.
Stock Fundamentals for LENZ
The total capital return value is set at -0.27. Equity return is now at value -28.64, with -24.49 for asset returns.
Based on LENZ Therapeutics Inc (LENZ), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -60.96.
Currently, EBITDA for the company is -122.24 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 28.63.
Conclusion
In conclusion, LENZ Therapeutics Inc (LENZ) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
